Overview

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Status:
RECRUITING

Trial end date:
2027-01-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

Phase:

PHASE2

Details

Lead Sponsor:

Celgene